You are here

Core One Labs Inc.

Listing Exchange: 
CSE
Status: 
Active
Industry: 
Life Sciences
Symbol: 
COOL
CSE Index: 
Currency: 

Core One Labs Inc. is a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy.  The Company has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. With this technology, the Company intends to further develop its IP technology to focus on delivering psychedelic molecules with an initial focus on psilocybin. Core One also holds an interest in walk-in medical clinics which maintain a database of over 200,000 patients combined. Through research and development in these clinics, including the integration of its intellectual property related to psychedelic treatments and novel drug therapies, the Company intends to work towards regulatory approval for research that advances psychedelic-derived treatments for mental health disorders.

You are here

Core One Labs Inc. (COOL)

SEDAR Information

Company Info

Address
Suite 800-1199 West Hastings Street
Vancouver, BC V6E 3T5
Canada
Phone
236-521-0626
Email
Info@core1labs.com
Website
HTTP://www.core1labs.com
Listing date
Wednesday, August 17, 2011
Transfer Agent
Computershare Investor Services Inc.
Investor Relations
Stride Report Inc.
Email
info@core1labs.com
Auditor
HDCPA Professional Corporation

Capitalization

Issued & Outstanding: 
47097332
Reserved for Issuance: 
4710562

Company Officers

Joel Shacker, Chief Executive Officer
Geoff Balderson, Chief Financial Officer & Corporate Secretary

Bulletins

14/07/2021

2021-0713 – Consolidation - Core One Labs Inc. (COOL)

le 14 juillet/July 2021

Core One Labs Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidation common share for every eight (8) pre-consolidation common shares.

As a result, the outstanding shares of the company will be reduced to approximately 14,344,076 common shares.

The name and symbol will not change.